| 2 year outcome . | . | OS . | LFS . | RI . | NRM . |
|---|---|---|---|---|---|
| all patients | haplo | 44+/-5 | 35+/-4 | 31+/-4 | 34+/-3 |
| auto | 62+/-3 | 47+/-3 | 44+/-3 | 9+/-2 | |
| <0,0001 | 0,02 | 0,0004 | <0,0001 | ||
| CR1 patients | haplo (125) | 49+/-5 | 40+/-5 | 29+/-5 | 30+/-4 |
| auto (250) | 65+/-4 | 50+/-4 | 41+/-4 | 9+/-2 | |
| 0,002 | 0,13 | 0,005 | <0,0001 | ||
| CR2 patients | haplo (59) | 31+/-7 | 24+/-7 | 35+/-8 | 41+/-7 |
| auto (109) | 57+/-6 | 39+/-6 | 49+/-6 | 10+/-4 | |
| 0,003 | 0,09 | 0,04 | <0,0001 |
| 2 year outcome . | . | OS . | LFS . | RI . | NRM . |
|---|---|---|---|---|---|
| all patients | haplo | 44+/-5 | 35+/-4 | 31+/-4 | 34+/-3 |
| auto | 62+/-3 | 47+/-3 | 44+/-3 | 9+/-2 | |
| <0,0001 | 0,02 | 0,0004 | <0,0001 | ||
| CR1 patients | haplo (125) | 49+/-5 | 40+/-5 | 29+/-5 | 30+/-4 |
| auto (250) | 65+/-4 | 50+/-4 | 41+/-4 | 9+/-2 | |
| 0,002 | 0,13 | 0,005 | <0,0001 | ||
| CR2 patients | haplo (59) | 31+/-7 | 24+/-7 | 35+/-8 | 41+/-7 |
| auto (109) | 57+/-6 | 39+/-6 | 49+/-6 | 10+/-4 | |
| 0,003 | 0,09 | 0,04 | <0,0001 |